EMEA-001254-PIP01-11-M02

Key facts

Active substance
  • Split influenza virus, inactivated containing antigens equivalent to the B-like strain (B/Yamagata lineage)
  • Split influenza virus, inactivated containing antigens equivalent to the B-like strain (B/Victoria lineage)
  • Split influenza virus, inactivated (B/Victoria lineage)
  • Split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain
  • Split influenza virus, inactivated containing antigens equivalent to the A/H3N2-like strain
Therapeutic area
Vaccines
Decision number
P/0129/2017
PIP number
EMEA-001254-PIP01-11-M02
Pharmaceutical form(s)
Suspension for injection
Condition(s) / indication(s)
Prevention of influenza infection
Route(s) of administration
  • Subcutaneous use
  • Intramuscular use
Contact for public enquiries
Sanofi Pasteur SP
France
Tel. +33 4373 75038
E-mail: piplan@sanofipasteur.com
Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-C-001254-PIP01-11-M02
Compliance opinion date
23/06/2017
Compliance outcome
positive

Decision

How useful was this page?

Add your rating